Anaemia: Does the KDIGO guideline move the needle in CKD anaemia?

作者信息

Singh Ajay K

出版信息

Nat Rev Nephrol. 2012 Nov;8(11):616-8. doi: 10.1038/nrneph.2012.218. Epub 2012 Sep 25.

DOI:10.1038/nrneph.2012.218

PMID:23007621

Abstract

摘要

相似文献

Anaemia: Does the KDIGO guideline move the needle in CKD anaemia?

Nat Rev Nephrol. 2012 Nov;8(11):616-8. doi: 10.1038/nrneph.2012.218. Epub 2012 Sep 25.

Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1269-1280. doi: 10.2215/CJN.00080116. Epub 2016 May 16.

Patient independence in chronic kidney disease and anaemia: implications of the 2012 KDIGO guideline.

J Ren Care. 2013 Jun;39(2):108-17. doi: 10.1111/j.1755-6686.2013.12010.x.

Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).

Nephrol Dial Transplant. 2009 Feb;24(2):348-54. doi: 10.1093/ndt/gfn653. Epub 2008 Nov 26.

Therapy of anemia: is it only a number to reach or are there other variables to control?

Blood Purif. 2013;36(1):37-40. doi: 10.1159/000350584. Epub 2013 May 25.

Anaemia: The safety and efficacy of peginesatide in patients with CKD.

Nat Rev Nephrol. 2013 Apr;9(4):192-3. doi: 10.1038/nrneph.2013.42. Epub 2013 Mar 12.

International treatment guidelines for anaemia in chronic kidney disease - what has changed?

Med J Aust. 2013 Jul 22;199(2):84-5. doi: 10.5694/mja13.10538.

Why does the treatment of anaemia not improve cardiac outcomes in CKD?

Nat Rev Nephrol. 2013 Jan;9(1):59-61. doi: 10.1038/nrneph.2012.239. Epub 2012 Oct 16.

[Use of erythropoiesis stimulating agents].

J Bras Nefrol. 2014 Mar;36(1 Suppl 1):19-23. doi: 10.5935/0101-2800.2014s006.

Anaemia in chronic kidney disease: what do new generation agents offer?

Lancet. 2022 Feb 19;399(10326):702-703. doi: 10.1016/S0140-6736(22)00120-9. Epub 2022 Jan 25.

引用本文的文献

Anemia among Chinese patients with chronic kidney disease and its association with quality of life - results from the Chinese cohort study of chronic kidney disease (C-STRIDE).

BMC Nephrol. 2021 Feb 22;22(1):64. doi: 10.1186/s12882-021-02247-8.

Drug development: how academia, industry and authorities interact.

Nat Rev Nephrol. 2014 Oct;10(10):602-10. doi: 10.1038/nrneph.2014.133. Epub 2014 Aug 5.

本文引用的文献

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.

Circulation. 2011 Dec 20;124(25):2903-8. doi: 10.1161/CIRCULATIONAHA.111.030411. Epub 2011 Nov 21.

ESAs in dialysis patients: are you a hedgehog or a fox?

J Am Soc Nephrol. 2010 Apr;21(4):543-6. doi: 10.1681/ASN.2010020178.

Does TREAT give the boot to ESAs in the treatment of CKD anemia?

J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.

Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.

J Am Soc Nephrol. 2007 Mar;18(3):975-84. doi: 10.1681/ASN.2006091034. Epub 2007 Jan 31.

Correction of anemia with epoetin alfa in chronic kidney disease.

N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485.

Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

N Engl J Med. 2006 Nov 16;355(20):2071-84. doi: 10.1056/NEJMoa062276.

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

N Engl J Med. 1998 Aug 27;339(9):584-90. doi: 10.1056/NEJM199808273390903.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验